Скринінг протипоказань перед вакцинацією — separating true contraindications from precautions and common misconceptions before immunization
A true contraindication is a condition in a recipient that greatly increases the risk of a serious adverse reaction — the vaccine should not be administered. The two universally recognized true contraindications for essentially all vaccines are a severe allergic reaction (anaphylaxis) after a previous dose of the same vaccine, and a known severe allergy to a component of the vaccine (e.g., certain excipients). Screening for these is the first and most safety-critical step of any pre-vaccination assessment.
Two categories dominate true-contraindication screening:
1. Severe allergic reaction to a previous dose: • Anaphylaxis (urticaria + respiratory or cardiovascular compromise) occurring after a prior dose of the SAME vaccine or a vaccine sharing the relevant component • Onset typically within minutes to an hour of administration • Confirmed cases should not receive further doses of that vaccine outside a specialist/allergy setting with resuscitation capability
2. Known severe allergy to a vaccine component: • Certain excipients (e.g., specific stabilizers, adjuvants, or trace culture-medium proteins) have documented allergic potential in a small subset of recipients • A confirmed severe allergy to a specific component contraindicates any vaccine containing that component • Component-specific — does NOT automatically contraindicate other vaccines that do not share the allergen
The key screening question is always: "Has this exact reaction happened before, to this exact vaccine or component, and was it truly severe/anaphylactic?" Vague reports of "a reaction" that were mild, delayed, or unrelated to the injection do not meet the bar for a true contraindication and should be characterized more precisely before any vaccine is withheld.
A true contraindication means the risk of vaccination outweighs the risk of the disease for this specific vaccine in this specific person. It is deliberately a narrow category — over-diagnosing contraindications leaves people unnecessarily unprotected.
Before flagging a true contraindication, the screener should establish:
• Timing: did symptoms begin within the expected window (minutes to about an hour) after the dose? • Symptom pattern: hives/urticaria plus airway, breathing, or circulation involvement — versus a benign, self-limited local or systemic reaction (e.g., soreness, low-grade fever, fussiness) • Which vaccine and which component: some reactions are to a specific component present in only some vaccine formulations, not the antigen itself • Medical confirmation: emergency treatment received (epinephrine), allergist follow-up, or documented skin testing
When the history is clear and severe, the vaccine (or any product sharing the implicated component) is withheld and the case is referred for specialist allergy evaluation, which may include component testing and a supervised graded challenge in some cases. When the history is unclear, screening should default to gathering more information rather than assuming either a contraindication or a precaution — misclassification in either direction has real consequences.
A precaution is a condition that might increase the risk of a reaction, or might compromise the vaccine's ability to produce immunity, but does NOT carry the same categorical risk as a true contraindication. The critical practical distinction: a precaution usually means deferring the vaccine until the condition resolves, whereas a true contraindication means the vaccine is avoided altogether (for that product). Confusing the two leads either to unsafe vaccination or to unnecessary, indefinite postponement.
Typical precautions include:
• Moderate or severe acute illness, with or without fever — vaccination is deferred until the person has recovered, both to avoid attributing new symptoms to the vaccine and to ensure the immune response is not blunted • A condition that might increase the chance of a specific known adverse event with a specific vaccine (product-specific precautions vary by vaccine and are listed in product-specific guidance) • A recent receipt of antibody-containing blood products, which can interfere with the immune response to certain live vaccines and warrants a spacing interval, not avoidance
Unlike a true contraindication, a precaution is a "weigh the risks and benefits" situation: in an outbreak or high-exposure setting, a clinician may reasonably proceed despite a precaution if the benefit clearly outweighs the theoretical added risk.
A simple triage sequence keeps precautions and contraindications from being conflated:
1. Is there a documented severe allergic reaction to a prior dose or a vaccine component? → True contraindication. Do not vaccinate; refer for specialist evaluation. 2. If not — is there a moderate/severe acute illness, or another recognized precaution condition, present right now? → Precaution. Defer the dose; reassess when the condition resolves. 3. If neither of the above — proceed with vaccination.
This three-branch logic is the backbone of every immunization screening checklist and should be applied consistently, resisting the temptation to treat any unfamiliar symptom or history as an automatic contraindication.
Precaution ≠ contraindication. A precaution answers "should we wait?" — a contraindication answers "should we ever give this?" Mixing up the two either exposes a patient to unnecessary risk or leaves them under-immunized for months.
A large share of the value of a structured screening process comes from correctly identifying what is NOT a contraindication or precaution. Mild illness, current antibiotic therapy, breastfeeding, and most allergies unrelated to vaccine components are frequently — and incorrectly — treated as reasons to delay vaccination. Each unnecessary deferral is a missed opportunity for protection and an added burden on the patient and health system.
Screening checklists exist specifically to catch these recurring misconceptions:
• Mild illness: a common cold, low-grade fever, or general malaise without a moderate/severe illness picture is NOT a reason to defer. Waiting for a "perfectly well" visit indefinitely delays protection with no safety benefit.
• Antibiotic use: antibiotics treat bacterial infections and do not suppress or interact with the immune response generated by vaccines. Being "on antibiotics" is not itself a reason to delay any vaccine.
• Breastfeeding: breastfeeding is compatible with essentially all vaccines for both the lactating parent and the infant. It is not a contraindication and is not typically even a precaution.
• Allergies unrelated to vaccine components: a food allergy, environmental allergy (e.g., pollen, dust), or an allergy to a medication that is not a vaccine ingredient does not predict a reaction to the vaccine and should not trigger deferral or referral.
Unnecessary deferrals are not a "safe default" — they carry costs:
• Missed protection during the deferral window, including during periods of active disease circulation • Additional visits and administrative burden for patients and clinics • Erosion of trust when patients are told conflicting things at different visits • A cumulative population-level effect: many small, unnecessary individual deferrals add up to reduced coverage
A well-designed screening tool therefore treats "ruling out false positives" as an explicit, first-class step — not an afterthought — right alongside identifying genuine contraindications and precautions.
Good screening is bidirectional: it must catch true contraindications AND actively clear people who have no real reason to be deferred. A checklist that only looks for reasons to say "no" will over-defer; it must also be built to say "proceed" with confidence.
Some recipient characteristics interact specifically with vaccine PLATFORM rather than with a given vaccine in isolation. Immunocompromise, pregnancy, and certain ages primarily affect eligibility for LIVE attenuated vaccines, because a live, replicating (even weakened) organism carries a theoretical risk of causing disease in a host who cannot adequately control it. Inactivated vaccines contain no live organism and are generally still considered appropriate in these same populations.
Live attenuated vaccines contain a weakened form of the actual pathogen that replicates transiently in the recipient to generate immunity. In a person with significantly impaired immune function, that limited replication may not be reliably contained, creating a theoretical risk of vaccine-strain disease. In pregnancy, the theoretical concern is a possible (not established, but not excluded) effect of a replicating organism on the fetus, so live vaccines are generally deferred until after delivery.
Inactivated vaccines (killed whole organism, subunit, protein, conjugate, or mRNA/viral-vector non-replicating platforms) contain no organism capable of causing the disease. There is no replication risk, so these platforms are generally considered appropriate for immunocompromised and pregnant individuals, following the same general precaution logic as anyone else (e.g., defer only for moderate/severe acute illness).
This is why the SAME clinical question — "is this person immunocompromised or pregnant?" — produces a DIFFERENT screening answer depending on whether the vaccine under consideration is live or inactivated.
A practical special-population check layers on top of the core contraindication/precaution logic:
1. Confirm vaccine platform: live attenuated, or inactivated/non-replicating? 2. If live: screen specifically for immunocompromise (and its degree/severity), pregnancy, and any vaccine-specific age floor or ceiling. A positive finding here generally means avoiding the live vaccine now, with a plan to reassess after the pregnancy ends or the immunocompromising condition resolves/stabilizes, or to use an inactivated alternative if one exists for that disease. 3. If inactivated: standard eligibility applies — immunocompromise, pregnancy, and age are not, by themselves, reasons for exclusion, though normal precaution rules (e.g., acute illness) still apply.
Age deserves its own note: some live vaccines have minimum-age thresholds tied to how the immune system matures, and some inactivated vaccines have their own age-based dosing schedules — always check the specific product's age indications rather than applying a single universal age rule.
The platform question — live vs. inactivated — should be asked before, not after, evaluating immunocompromise, pregnancy, and age. The same patient can be fully eligible for an inactivated vaccine while needing to defer a live one on the very same visit.
Every screening encounter should end with an explicit, recorded decision, not an implicit one. The three possible outputs are: proceed with vaccination now; defer, with the specific reason and a plan for reassessment; or true contraindication, with the reason documented and an alternative plan (a different vaccine, product, or timing) discussed. Clear documentation protects the patient, informs the next clinician, and closes the loop on deferred doses so they are not simply forgotten.
A well-formed documentation entry captures:
• The specific screening question(s) asked and the answers given • The classification reached: no concern, precaution, or true contraindication — and which specific finding drove that classification • For "proceed": confirmation that the dose was given, product, lot, site • For "defer": the precise reason (e.g., "moderate acute illness with fever"), and a concrete reassessment trigger or date (e.g., "reschedule once afebrile for 24h" or "reassess at next well visit") • For "true contraindication": the reason, whether it is component-specific or vaccine-specific, and the alternative plan — an alternative product without the implicated component, an alternative route, or referral to an allergy/immunization specialist
Vague notes like "will give later" or "patient reaction, hold off" without a specific reason and a specific next step are a common source of doses that are deferred and then never revisited.
Documentation is only useful if it drives action:
• Deferred (precaution) doses should be flagged for active follow-up — a callback, a reminder at the next visit, or a system prompt — rather than left to the patient to remember • True contraindications should trigger a documented alternative plan at the same visit whenever possible, so the patient leaves with a path forward instead of an open question • The record should be visible to any future clinician, so screening is not repeated from scratch and prior true contraindications are not accidentally re-tested
A screening tool is only as good as the decision it produces and the follow-through that decision enables — the goal is always maximal safe protection, achieved through precise, well-documented decisions rather than blanket caution.
The purpose of contraindication screening is not to find reasons to withhold vaccines — it is to vaccinate as many people as safely as possible, by precisely identifying the small number of situations where withholding or deferring truly is the safer choice.